Chargement en cours...
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia
The safety and efficacy of ibrutinib, an oral inhibitor of Bruton tyrosine kinase, were evaluated with chemoimmunotherapy (CIT) in a multicenter phase 1b study. Patients with relapsed/refractory chronic lymphocytic leukemia received bendamustine and rituximab (BR) or fludarabine, cyclophosphamide, a...
Enregistré dans:
| Publié dans: | Blood |
|---|---|
| Auteurs principaux: | , , , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Society of Hematology
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4424415/ https://ncbi.nlm.nih.gov/pubmed/25755291 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-09-585869 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|